1333400-84-2

Basic information

• Product Name: 3-bromo-4-((tert-butoxycarbonyl)methyl)benzoic acid
• Synonyms: 3-bromo-4-((tert-butoxycarbonyl)methyl)benzoic acid;3-bromo-4-(((tert-butoxycarbonyl)amino)methyl)benzoic acid
• CAS NO: 1333400-84-2
• Molecular Formula: C₁₃H₁₆BrNO₄
• Molecular Weight: 315.1598
• Mol File: 1333400-84-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-bromo-4-((tert-butoxycarbonyl)methyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-4-((tert-butoxycarbonyl)methyl)benzoic acid(1333400-84-2)
• EPA Substance Registry System: 3-bromo-4-((tert-butoxycarbonyl)methyl)benzoic acid(1333400-84-2)

Safety Data

• Hazardous Substances Data: 1333400-84-2(Hazardous Substances Data)

Upstream product

• 1333400-86-4 3-bromo-4-(tert-butoxycarbonylamino-methyl)benzoic acid methyl ester 
• 1333400-85-3 diBoc-4-aminomethyl-3-bromo-benzoic acid methyl ester 
• 78946-25-5 3-bromo-4-(bromomethyl)benzoic acid methyl ester 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 7697-26-9 3-bromo-4-methylbenzoic acid 

Downstream Products

• 1333400-87-5 [2-bromo-4-(pyridin-4-ylcarbamoyl)-benzyl]-carbamic acid tert-butyl ester 
• 1333400-46-6 tetrahydrofuran-2-ylmethyl 2'-(aminomethyl)-5'-{[(3-fluoropyridin-4-yl)amino]carbonyl} biphenyl-3-carboxylate 
• 1333400-45-5 C₂₆H₂₆FN₃O₄ 
• 1333400-47-7 C₂₄H₂₂FN₃O₃ 
• 1333400-24-0 C₂₅H₂₄FN₃O₃ 
• 1333400-25-1 C₂₆H₂₆FN₃O₃ 
• 1333398-79-0 2'-aminomethyl-5'-(pyridin-4-ylcarbamoyl)-biphenyl-3-carboxylic acid cyclohexyl methyl ester 
• 1333398-78-9 2'-aminomethyl-5'-(pyridin-4-ylcarbamoyl)-biphenyl-3-carboxylic acid cyclopentylmethyl ester 
• 1333400-15-9 C₂₆H₂₀FN₃O₃ 
• 1333398-75-6 2'-aminomethyl-5'-(pyridin-4-ylcarbamoyl)-biphenyl-3-carboxylic acid cyclohexyl ester 
• 1333400-88-6 [2-bromo-4-{3-fluoro-pyridin-4-ylcarbamoyl}-benzyl]-carbamic acid tert butyl ester 

Relevant articles and documents

3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors

Clinical development of ROCK inhibitors has so far been limited by systemic or local ROCK-associated side effects. A soft drug approach, which involves predictable metabolic inactivation of an active compound to a nontoxic metabolite, could represent an a